Evaluation of hypotensive efficacy, tolerability and safety of Brinzopt carbonohydrase inhibitor in glaucoma therapy and correction of postoperative ophthalmic hypertension in patients with cataract

PURPOSE: To evaluate the antihypertensive efficacy and safety of Brinzopt (Brinzolamide) in patients with POAG and in patients with transient postoperative ocular hypertension following phacoemulsification. METHODS: A total of 56 patients aged from 46 to 82 years (mean age 64 years) were enrolled. Group I included 20 patients (26 eyes) with newly diagnosed primary open-angle glaucoma, mainly the initial stages (the initial corneal compensated IOP (IOPcc) ranged from 21 to 25 mm Hg). Group II comprised 20 patients (23 eyes) with initial and advanced stages of POAG and decompensated IOPcc on prostaglandin monotherapy. Group III consisted of 16 patients (16 eyes) with reactive ocular hypertension ranged from 21 to 25 mmHg developed in the early postoperative period after senile cataract phacoemulsification. All patients received Brinzopt as monotherapy or in combination with previously used antihypertensive agents in one or both eyes twice daily at 12 hour intervals. Registration of the investigated parameters was carried out at the beginning of the study, and at intervals of 1 week, 2 weeks and 3 months under treatment. In addition to standard ophthalmologic examination patients underwent static perimetry on the Humphrey Visual Field Analyzer II (HFA II) 750i (Germany), ophthalmotonometry using dynamic ORA (Ocular Response Analyzer, USA) and optical coherence tomography (OCT) of the retina and the optic nerve head by means of RTVue-100 (Optovue, USA). RESULTS: Patients of the first two groups used Brinzopt during the entire follow-up period. In Group III Brinzopt instillations were cancelled by the end of the second month after the development of moderate hypotension against the background of reactive postoperative inflammation subsidence and corticosteroid withdrawal. Hypotensive efficacy of Brinzopt by the end of the follow-up period in Group I was 16.6%, in the second group — 13%, in the third group — 16.9%. CONCLUSION: Brinzopt is a safe, well-tolerated drug. It has a sufficient and fairly persistent antihypertensive effect as well as a positive influence on morphofunctional state of the optic nerve head and retina. It also doesn’t have a systemic effect and is comfortable for patients. The investigated drug makes it possible to achieve rapid and stable IOP normalization and enhance the abatement of reactive inflammatory process in early postoperative period after phacoemulsification in patients with symptomatic ocular hypertension.

1. Либман Е.С., Шахова Е.В. Состояние слепоты и динамика слепоты и инвалидности вследствие патологии органа зрения в России. Тезисы докладов VII съезда офтальмологов России. М., 2000; 209-215. [Libman E.S., Shakhova E.V. Situation of blindness and disability due to vision organ pathology in Russia. Abstracts of VII Congress of Russian ophthalmologists. Moscow, 2000; 209-215. (In Russ.)].

2. Глаукома. Национальное руководство. Под ред. Егорова Е.А. М.: ГЭОТАР-Медиа, 2013; 824 с. [Glaukoma. Natsional’noye rukovodstvo. [Glaucoma. National guidelines.]. Ed. by Egorov E.A. Moscow, GEOTAR-Media Publ., 2013; 824 p. (In Russ.)].

3. Ловпаче Дж.Н. Опыт применения фиксированной комбинации Дорзопт плюс у пациентов с различными клиническими разновидностями глаукомы. Российский офтальмологический журнал 2013; 6(1):92-95. [Lovpache J.N. An experience of using a fixed combination Dorsopt Plus in patients with various clinical forms of primary open-angle glaucoma. Russian Ophthalmological J 2013: 6(1):92-95. (In Russ.)].

4. Нестеров А.П. Глаукома. М., 2008; 360 с. [Nesterov A.P. Glaukoma [Glaucoma]. Moscow, 2008; 360 p. (In Russ.)].

5. Морозов В.И., Яковлев А.А. Фармакотерапия глазных болезней. М.: Медицина, 2001; 472 с. [Morozov V.I., Yakovlev A.A. Farnakoterapiya glaznykh boleznei. [Pharmacotherapy of eye diseases]. Moscow, Medicine Publ., 2001; 472 p. (In Russ.)].

6. Макогон С.И., Макогон А.С. Исследование коморбидности у пациентов разных возрастных групп с первичной откры- тоугольной глаукомой. Национальный журнал глаукома 2017; 16(1):5-14. [Makogon S.I., Makogon A.S. The study of comorbidity in patients with primary open-angle glaucoma in different age groups. Natsional’nyi zhurnal glaucoma 2017; 16(1):5-14. (In Russ.)].

7. Макогон С.И., Макогон А.С. Анализ причин низкой приверженности к лечению у пациентов с первичной открытоугольной глаукомой. Вестник современной клинической медицины 2015; 6:52-57. [Makogon S.I., Makogon A.S. Analysis of the causes of low adherence to treatment in patients of primary open-angle glaucoma. Vestnik sovremennoy klinicheskoy meditsiny 2015; 6:52-57. (In Russ.)].

8. Малеванная О.А., Алексеев В.Н., Суркова В.С. Изучение приверженности к лечению у больных первичной открытоугольной глаукомой. Глаукома: теория и практика: сб. науч. тр. конф. СПб., 2013: 83-92. [Malevannaya O.A., Alekseev V.N., Surkova V.S. Study adherence to treatment in patients with primary open-angle glaucoma. St. Petersburg, 2013: 83-92. (In Russ.)].

9. Онищенко А.Л., Лихачева И.Г., Ткачев В.А., Пластинина С.Л. Изучение факторов недостаточной приверженности к лечению больных первичной глаукомой. Национальный журнал глаукома 2009; 3:32-34. [Onishchenko A.L., Likhacheva I.G., Tkachev V.A., Plastinina S.L. Study of the factors of insufficient adherence to treatment of patients with primary glaucoma. Natsional’nyi zhurnal glaucoma 2009; 3:32-34. (In Russ.)].

10. Егоров Е.А., Астахов Ю.С., Ставицкая Т.В. Офтальмофармакология. М.: ГЭОТАР-Медиа, 2005; 464 с. [Egorov E.A., Astakhov Yu.S., Stavitskaya Т.V. Oftalmofarmakologiya. [Ophthalmopharmacology]. Moscow, GEOTAR-Media Publ., 2005; 464 p. (In Russ.)].

11. Еричев В.П. Современные принципы гипотензивной терапии глаукомы. Cб. науч. статей. М., 2008: 220-223. [Erichev V.P. Modern principles of antihypertensive therapy of glaucoma. Collection of scientific articles. Moscow, 2008: 220-223. (In Russ.)].

12. Нестеров А.П., Егоров Е.А. Медикаментозное гипотензивное лечение глаукомы. Клиническая фармакология и терапия 1994; 3(2):86-88. [Nesterov A.P., Egorov E.A. Drug-induced hypotensive treatment of glaucoma. Klinicheskaya farmakologiya i terapiya 1994; 3(2):86-88. (In Russ.)].

13. Sugrue M.F. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000; 19(1):87-112.

14. Bayer A., Ferrari F., Maren T.H., Erb C. Topical carbonic anhydrase inhibitors in the treatment of glaucoma. J Fr Ophtalmol 1996; 19(5):357-362.

15. Егоров А.Е. Изучение гипотензивного действия и побочных эффектов ингибитора карбоангидразы дорзоламида гидрохлорида. Вестник офтальмологии 1996; 2:3-4. [Egorov A.E. A study of the hypotensive effect and side effects of the carboanhydrase inhibitor dorzolamide hydrochloride. Vestn oftalmol 1996; 2:3-4. (In Russ.)].

16. Silver L.H. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open– angle glaucoma and ocular hypertension. Am J Ophthalmol 1998; 126(3):400-408.

17. Silver L.H. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000; 44(2):141-145.

18. Аветисов С.Э., Сафонова Т.Н., Новиков И.А., Патеюк Л.С., Грибоедова И.Г. Кислотность и буферная система глазной поверхности (по данным исследования конъюнктивальной полости. Вестник офтальмологии 2014; 130(5):5-10. [Avetisov S.E., Safonova T.N., Novikov I.A., Pateiuk L.S., Griboedova I.G. Ocular surface acidity and buffering system (by studying the conjunctival sac). Vestn oftalmol 2014; 130(5):5-10. (In Russ.)].

19. Рябцева А.А. Реактивная гипертензия после экстракции катаракты. Автореферат дисс. … канд. мед. наук. М.: 1988; 20 с. [Ryabtseva A.A. Reactive hypertension after cataract extraction abstract. PhD dissertation abstract. Moscow, 1988. 20 p. (In Russ.)].

20. Нестеров А.П. Глаукома. М.: Медицина, 1995; 256 с. [Nesterov A.P. Glaukoma [Glaucoma]. Moscow, Meditsina Publ., 1995; 256 p. (In Russ.)].

21. Самойлов А.Я. Реактивная гипертензия глаза. М., 1926; 84 с. [Samoylov A.Ya. Reaktivnaya gipertenziya glaza. [Reactive hypertension of the eye]. Moscow, 1926; 84 p. (In Russ.)].

22. Арутюнян Л.Л., Анисимов С.И., Анисимова С.Ю., Полякова К.М. Гипотензивная эффективность ингибитора карбоангидразы Дорзопта при послеоперационной офтальмогипертензии у пациентов с катарактой и первичной открытоугольной глаукомой. Российский офтальмологический журнал 2013; 4:1-5. [Arutyunyan L.L., Anisimov S.I., Anisimova S.Yu., Polyakova K.M. The hypotensive effect of Dorzopt in the treatment of postoperative eye hypertension in patients with cataract and primary open-angle glaucoma. Russian Ophthalmological J 2013; 4:1-5. (In Russ.)].

23. Sandu P., Stefaniu I., Zamfir C. Premature elevated intraocular pressure after cataract surgery. Oftalmologia 2001; 54(4):61-64.

24. Menon G.J., Vernon S.A. Topical brinzolamide and metabolic acidosis. Br J Ophthalmol 2006; 90:247-248.